Genetic and Molecular Profiling of PLIN5 and LCN2 in Hepatocellular Carcinoma: Implications for Diagnosis and Prognosis

Background: Hepatocellular carcinoma (HCC) is a major global health challenge, often diagnosed at advanced stages, necessitating reliable biomarkers for early detection and prognosis. Objectives: This study investigates the mRNA expression levels and polymorphisms of perilipin 5 (PLIN5) and lipocalin 2 (LCN2) in liver tissues of HCC patients compared to healthy controls, alongside histopathological analyses. Methods: In a case-control study involving 50 HCC patients and 50 healthy liver donors, we quantified PLIN5 and LCN2 mRNA expression using Real-Time PCR, genotyped PLIN5 (rs1062223 G>A) and LCN2 (rs11556770 G>T) polymorphisms, and assessed stereological parameters including hepatocyte count, hepatocyte volume, Kupffer cell count, and fibrotic tissue volume. Results: Results showed significantly elevated PLIN5 and LCN2 mRNA expression in HCC tissues (P < 0.05). The PLIN5 rs1062223 A allele was significantly more frequent in HCC patients (P = 0.031), suggesting its role as a risk factor, while LCN2 rs11556770 showed no significant genotypic differences. Histopathologically, HCC tissues exhibited reduced hepatocyte and Kupffer cell counts, increased hepatocyte volume, and higher fibrotic tissue volume (P < 0.05). Conclusions: These findings highlight the pleiotropic roles of PLIN5 and LCN2 in HCC pathogenesis, suggesting their potential as candidate biomarkers, pending further validation.

• Publication year

  2025

• Venue

  International Journal of Infection

• Publication date

  2025-07-31

• Fields of study

  Not labeled

• Identifiers
  DOI 10.5812/iji-167377
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Perilipin 5 regulates hepatic stellate cell activation and high‐fat diet‐induced non‐alcoholic fatty liver disease

  2023cited by this paper
• Plin5 Bidirectionally Regulates Lipid Metabolism in Oxidative Tissues

  2022cited by this paper
• Pathogenesis of primary liver carcinomas.

  2022cited by this paper
• Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

  2021cited by this paper
• Hepatocellular carcinoma incidence at national and provincial levels in Iran from 2000 to 2016: A meta-regression analysis

  2021cited by this paper
• A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma

  2021cited by this paper
• Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights

  2021cited by this paper
• Lipocalin-2: Structure, function, distribution and role in metabolic disorders.

  2021cited by this paper
• Perilipin-5 as a potential new biomarker in patients with liver disease and impaired De Ritis ratio

  2021cited by this paper
• Inflammatory Mechanisms of HCC Development

  2020cited by this paper
• Progress and prospects of biomarkers in primary liver cancer (Review).

  2020cited by this paper
• Perilipin 5 promotes hepatic steatosis in dairy cows through increasing lipid synthesis and decreasing very low density lipoprotein assembly.

  2019cited by this paper
• Perilipin 5 and Lipocalin 2 Expression in Hepatocellular Carcinoma

  2019cited by this paper
• Oleic acid-induced perilipin 5 expression and lipid droplets formation are regulated by the PI3K/PPARα pathway in HepG2 cells.

  2019cited by this paper
• Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cited by this paper
• The Perilipins: Major Cytosolic Lipid Droplet-Associated Proteins and Their Roles in Cellular Lipid Storage, Mobilization, and Systemic Homeostasis.

  2016cited by this paper
• Perilipin 5 improves hepatic lipotoxicity by inhibiting lipolysis

  2015cited by this paper

• No citing papers are available for this paper.